# E2211 (NCT01824875)

> Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01824875
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: ECOG-ACRIN Cancer Research Group
- Conditions: Gastrinoma; Glucagonoma; Insulinoma; Islet Cell Carcinoma; Pancreatic Polypeptide Tumor; Recurrent Islet Cell Carcinoma; Somatostatinoma
- Interventions: temozolomide; capecitabine
- Enrollment: 144
- Primary outcome: Progression-free Survival

## Indexed commentary on E2211 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- YouTube: 4
- X threads: 4
- Podcasts: 3
- Bluesky threads: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=e2211-nct01824875

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT01824875", "email": "<work email>"}; the inbox owner confirms by the emailed link.